Project Grant R01CA305915
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $659K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas at Austin $396,377 on May 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The project integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to uncover the mutational processes driving...
- The National Cancer Institute awarded the University of Texas Health Science Center at San Antonio $482,637 on June 16, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the mechanism of ring-between-ring ubiquitin signaling in DNA repair. The project focuses on the RBR E3 ligase ARIH1, a novel DNA damage response factor essential for double-strand break repair. The research will determine the molecular regulation of ARIH1 at damaged chromatin, define...
- The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $639,514 on June 1, 2026, for mechanistic characterization of NVL inhibition by benzothiazepinones as a non-genotoxic chemotherapy strategy under the Cancer Biology Research program (CFDA 93.396). The award funds research to define the catalytic mechanism of NVL, an essential AAA+ ATPase required for large ribosomal subunit...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Texas Health Science Center at San Antonio $433,976 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate molecular mechanisms of BRCA1/2-mediated genome stability maintenance. The funded research addresses homologous recombination pathways and DNA double-strand break repair in...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $150,898 to the University of Texas at Austin on June 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and validate gene activators of cancer cell-cell fusion that contribute to chromosomal instability and tumor evolution in triple negative breast cancer. The project will perform a pooled CRISPR activation screen in triple negative breast cancer cells to discover genes...
- The National Cancer Institute awarded the University of Texas Health Science Center at Houston $389,828 on September 15, 2025, under the Cancer Research Manpower program (CFDA 93.398) to model enhancer hijacking in cancer through genome engineering and single-cell sequencing. The award funds research led by Dr. Xu to investigate how structural variants rewire enhancer-promoter communication and drive oncogene activation in rearranged human genomes. The research employs CRISPR/CAS9 genome...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $402,011 to The University of Texas Southwestern Medical Center on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how the KEAP1-NRF2 redox-sensing pathway regulates CD8 T-cell adaptation to persistent antigen receptor signaling in cancer and chronic infection contexts. The funded research addresses T-cell exhaustion, a dysfunctional...
- The National Cancer Institute awarded $740,346 to The University of Texas MD Anderson Cancer Center on September 9, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393), a Project Grant classified as assistance funding. MD Anderson will develop efficient methods for measuring and characterizing genetic interactions in cancer cells using a CRISPR/Cas12a-based multiplexing system called IN4MER, which quantitates genetic interactions with five-fold fewer reagents than...
- The National Cancer Institute awarded the University of Texas at El Paso $573,746 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of N6-methyladenosine (M6A) modification in estrogen receptor activation and breast cancer progression. The research examines how M6A modification of enhancer RNAs facilitates phase-separated condensation of estrogen receptors, which is critical for assembling enhancer transcriptional machinery and regulating...